RPRX
Royalty Pharma plc Class A Ordinary Shares
$61.30
장중 · Vol 85.6K · 52주 $34.08–$62.45 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $60.63 · Aug 31, 2026
RPRX 가격 추세
종가
$60.63
시가
$60.81
고가
$60.90
저가
$60.41
30초 브리핑
RPRX 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 96%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 10.6배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-11-04
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Aug 31, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
RPRX 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Aug 31, 2026
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
110 East 59th Street · New York, NY, United States · 직원 100명
시가총액
$35.16B
Trailing P/E
32.7
최근 12개월 이익 기준
Forward P/E
10.6
이익 증가 기대 반영
EPS (TTM)
$1.86
배당 수익률
1.54%
배당성향
48.9%
베타
0.42
시장보다 방어적
ROE
14.0%
P/B
3.97
EV/EBITDA
24.5
52주 범위
$34.08 – $62.45
현재 위치 96%
거래량
1.94M
20일 평균 2.01M · 1.0배
애널리스트 의견
매수 88%
총 8명 · 0m
DITM LEAPS Analysis
RPRX 장기 DITM 콜옵션을 진입 적합도 순으로 비교
해당 종목의 옵션 데이터가 없습니다.
재무제표
RPRX 연간 손익·현금흐름·재무상태
매출 성장률
+5.1%
최근 연간 YoY
EPS 성장률
+23.1%
최근 연간 YoY
영업이익률
65.6%
최근 연간
FCF 마진
104.7%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $2.38B+5.1% | $2.26B-3.9% | $2.35B+5.2% | $2.24B |
| 매출총이익 | — | — | — | — |
| 영업이익 | $1.56B+20.7% | $1.29B-13.4% | $1.49B+61.7% | $922.89M |
| 순이익 | $770.95M-10.2% | $858.98M-24.3% | $1.13B+2549.5% | $42.83M |
| 희석 EPS | $1.78+23.1% | $1.45-42.8% | $2.53+2430.0% | $0.10 |
| EBITDA | $1.64B+5.1% | $1.56B-17.5% | $1.89B+345.4% | $423.69M |
| 영업현금흐름 | $2.49B-10.1% | $2.77B-7.3% | $2.99B+39.4% | $2.14B |
| 잉여현금흐름 | $2.49B-10.1% | $2.77B-7.3% | $2.99B+39.4% | $2.14B |
| 총자산 | $19.62B+7.7% | $18.22B+11.2% | $16.38B-2.6% | $16.81B |
| 총부채 | $8.95B+17.6% | $7.61B+24.1% | $6.14B-13.8% | $7.12B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
RPRX 실적·배당 일정
매출 하단
$855.00M
EPS 하단
$1.14
매출 상단
$891.54M
배당 지급일
2026-09-10
D-9
실적 발표일
2026-11-04
D-64
EPS 상단
$1.22
매출 컨센서스
$877.34M
EPS 컨센서스
$1.17
배당락일
2026-08-14
18일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 14, 2026 | $0.2350 |
| May 15, 2026 | $0.2350 |
| Feb 20, 2026 | $0.2350 |
| Nov 14, 2025 | $0.2200 |
| Aug 15, 2025 | $0.2200 |
| May 16, 2025 | $0.2200 |
| Feb 21, 2025 | $0.2200 |
| Nov 15, 2024 | $0.2100 |
뉴스
RPRX 관련 최신 기사
- 규제·법률
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.
Stocktwits · Aug 25, 2026
M&ARoyalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a […]
Insider Monkey · Aug 13, 2026
일반Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Zacks · Aug 13, 2026
제품·기술Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run
Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain. Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story. The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on...
Simply Wall St. · Aug 13, 2026
- 제품·기술
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate
Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase and sale deal with Royalty Pharma linked to rusfertide, a potential treatment for polycythemia vera. The agreement transfers Zealand Pharma's economic interests related to rusfertide, including potential future royalty rights. It also provides new funding that management plans to redeploy toward the company's key priorities...
Simply Wall St. · Aug 12, 2026
실적Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
Royalty receipts surged 14% as guidance raised for second consecutive quarter.
Motley Fool · Aug 12, 2026
- 실적
Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ...
Revolution Medicines Inc (RVMD) reports paradigm-changing Phase 3 results and a robust $3.9 billion cash position to fuel its commercial launch and expansive pipeline.
GuruFocus.com · Aug 6, 2026
- 실적
Revolution Medicines Q2 Earnings Call Highlights
Revolution Medicines (NASDAQ:RVMD) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer. The company
MarketBeat · Aug 6, 2026
- 실적
Royalty Pharma Q2 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline. Chief Executive Officer Pablo Legorreta said the company delivered 6% grow
MarketBeat · Aug 5, 2026
- 실적
Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance
Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.
GuruFocus.com · Aug 5, 2026
홀더
RPRX 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
87.4%
기관 보유 (유동주식)
93.4%
내부자 보유
6.5%
기관 수
992
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Morgan Stanley | 42.93M | $2.61B | 9.6% | -1.5% | Jun 30, 2026 |
| Capital International Investors | 35.27M | $2.15B | 7.9% | 0.8% | Jun 30, 2026 |
| Blackrock Inc. | 27.83M | $1.69B | 6.3% | 7.4% | Jun 30, 2026 |
| FMR, LLC | 24.51M | $1.49B | 5.5% | -2.5% | Jun 30, 2026 |
| State Street Corporation | 12.34M | $750.78M | 2.8% | 12.3% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 11.19M | $681.13M | 2.5% | 478.7% | Jun 30, 2026 |
| Swedbank AB | 10.73M | $652.71M | 2.4% | -7.4% | Jun 30, 2026 |
| BAILLIE GIFFORD & CO | 10.02M | $609.45M | 2.3% | -38.0% | Jun 30, 2026 |
| Capital World Investors | 9.52M | $579.13M | 2.1% | 18.4% | Jun 30, 2026 |
| Geode Capital Management, LLC | 8.06M | $490.33M | 1.8% | 2.4% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.